Update to the Biosimilar Preferred Drug List (PDL)
Effective January 4, 2024, the Department will add preferred and non-preferred drugs to the PDL.
The Department will add the following preferred drugs:
- Q5122 – Nyvepria, pegfilgrastim-apgf
The Department will add the following non-preferred drugs: